Design, synthesis and biological studies of novel tubulin inhibitors.
Sun Y., Pandit B., Chettiar SN., Etter JP., Lewis A., Johnsamuel J., Li P-K.
A series of compounds originally derived from the vascular endothelial growth factor receptor tyrosine kinase inhibitor, SU5416, were synthesized and evaluated. The most potent compound in this series, compound 3, which structurally resembles the potent anti-microtubule agent combretastatin A-4, inhibited tubulin polymerization and showed potent growth inhibitory activities on both prostate and breast cancer lines with IC50 values in the low nanomolar range.